Interstitial Control-Released Polymer Carrying a Targeting Small-Molecule Drug Reduces PD-L1 and MGMT Expression in Recurrent High-Grade Gliomas with TMZ Resistance

• Published in: Cancers 2022-02, Vol.14 (4), p.1051
• Main Authors: Liu, Ching-Ann, Liu, Wei-Hsiu, Ma, Hsin-I, Chen, Yuan-Hao, Hueng, Dueng-Yuan, Tsai, Wen-Chiuan, Lin, Shinn-Zong, Harn, Horng-Jyh, Chiou, Tzyy-Wen, Liu, Jen-Wei, Lee, Jui-Hao, Chiu, Tsung-Lang
• Format: Article
• Language: English
• Subjects: Adverse events; Apoptosis; Biodegradability; Brain cancer; Brain research; Brain tumors; Cell activation; Cell death; Chemotherapy; Clinical trials; Cytotoxicity; Deoxyribonucleic acid; DNA; DNA methyltransferase; Drug dosages; Edema; FDA approval; Genomes; Glioblastoma; Glioma; Good Manufacturing Practice; Immunotherapy; Lymphocytes T; Medical prognosis; Methylguanine; O6-methylguanine-DNA methyltransferase; Patients; PD-L1 protein; Polymers; Radiation therapy; Stem cells; Temozolomide; γ-Interferon
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14041051

In recurrent glioblastoma, Gliadel wafer implantation after surgery has been shown to result in incomplete chemical removal of residual tumor and development of brain edema. Furthermore, temozolomide (TMZ) resistance caused by O -methylguanine-DNA-methyltransferase (MGMT) activation and programmed cell death-ligand 1 (PD-L1) expression leads to immune-cold lesions that result in poorer prognosis. Cerebraca wafer, a biodegradable polymer containing (Z)- -butylidenephthalide (BP), is designed to eliminate residual tumor after glioma resection. An open-label, one-arm study with four dose cohorts, involving a traditional 3 + 3 dose escalation clinical trial, of the Cerebraca wafer combined with TMZ on patients with recurrent high-grade glioma, was conducted. Of the 12 patients who receive implantation of Cerebraca wafer, there were no drug-related adverse events (AEs) or serious AEs (SAEs). The median overall survival (OS) of patients receiving low-dose Cerebraca wafer was 12 months in the group with >25% wafer coverage of the resected tumor, which is longer than OS duration in previously published studies (Gliadel wafer, 6.4 months). Patients who received high-dose Cerebraca wafer treatment had not yet died at the data cut-off date; a 100% progression-free survival (PFS) rate at six month was achieved, indicating the median OS of cohort IV was more than 17.4 months. In vitro study of the primary cells collected from the patients revealed that the IC of BP against tumor stem cells was four times lower than that of bis-chloroethylnitrosourea (BCNU). A synergistic effect between BP and TMZ was demonstrated by a reduction in MGMT expression. Furthermore, BP inhibited PD-L1 expression, thereby activating T-cell cytotoxicity and increasing interferon-gamma (IFN-γ) secretion. The better therapeutic effect of Cerebraca wafer on recurrent high-grade glioma could occur through re-sensitization of TMZ and reduction of PD-L1.